Skip to main content
SpringerLink
Log in

Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Hepatocellular carcinoma (HCC) is one of the most common cancers with an increasing incidence and high mortality rate worldwide. Surgical resection is still an essential curative-intent treatment for improving the prognosis of patients with HCC. Due to the concomitance of HCC with cirrhosis, chronic liver disease, alcohol consumption and its complications, clinical treatment is challenging. Despite the rational approaches to prevention that have been developed, many patients are diagnosed at an advanced stage and are not eligible for surgical treatment, for example, because of poor underlying liver function or extrahepatic disease spread. The recurrence rates after curative resection still remain high. The implementation of neoadjuvant therapy in HCC management plays an important role in preventing tumor progression, but also shows promising results in downstaging HCC to enable surgical resection. The absence of randomized controlled trials leaves uncertainty in improving outcome, and consensus guidelines are lacking. In this review article, we summarize the clinical efficacy of evolving neoadjuvant treatments for patients with intermediate or advanced stage HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma. [Updated 2021 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559177/.

  2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019. Erratum in: J Hepatol. 2019;70(4):817.

    Article  Google Scholar 

  3. Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41–53. https://doi.org/10.2147/JHC.S61146.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Braunwarth E, Stättner S, Fodor M, Cardini B, Resch T, Oberhuber R, et al. Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. Eur Surg. 2018;50(3):100–12. https://doi.org/10.1007/s10353-018-0537-x.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–54.

    Article  CAS  PubMed  Google Scholar 

  6. Kulik L, Heimbach JK, Zaiem F, Almasri J, Prokop LJ, Wang Z, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67:381–400.

    Article  CAS  PubMed  Google Scholar 

  7. Li C, Wang MD, Lu L, Wu H, Yu JJ, Zhang WG, et al. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis. Hepatol Int. 2019;13:736–47.

    Article  PubMed  Google Scholar 

  8. Tustumi F, Ernani L, Coelho FF, Bernardo WM, Junior SS, Kruger JAP, et al. Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Ooxford). 2018;20:1109–18.

    Article  Google Scholar 

  9. Zhang T, Zhang L, Xu Y, Lu X, Zhao H, Yang H, et al. Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma. Am J Cancer Res. 2020;10(6):1658–67.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of Doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52. https://doi.org/10.1007/s00270-009-9711-7.

    Article  PubMed  Google Scholar 

  11. Song JE, Kim DY. Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol. 2017;9(18):808–14. https://doi.org/10.4254/wjh.v9.i18.808.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Zou JH, Zhang L, Ren ZG, Ye SL. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis. 2016;17(8):510–7. https://doi.org/10.1111/1751-2980.12380. PMID: 27384075.

    Article  CAS  PubMed  Google Scholar 

  13. Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology. 2013;60:813–20.

    CAS  PubMed  Google Scholar 

  14. Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:920–5.

    Article  CAS  PubMed  Google Scholar 

  15. Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol. 2015; https://doi.org/10.4254/wjh.v7.i16.2009.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther. 2016;33:699–714.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16:1587–96.

    Article  PubMed  Google Scholar 

  18. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, Gaba RC, Mulcahy MF, Baker T, Sato K, Hickey R, Ganger D, Riaz A, Fryer J, Caicedo JC, Abecassis M, Kulik L, Salem R. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59(5):1029–36. https://doi.org/10.1016/j.jhep.2013.06.015. Epub 2013 Jun 25. PMID: 23811303; PMCID: PMC5085290.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Bouazza F, Poncelet A, Garcia CA, et al. Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma. World J Gastroenterol. 2015;21(32):9666–70. https://doi.org/10.3748/wjg.v21.i32.9666.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Casadei Gardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, Sangro B. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther. 2018;11:7315–21. https://doi.org/10.2147/OTT.S175715.

    Article  PubMed  Google Scholar 

  21. Yang B, Liang J, Qu Z, Yang F, Liao Z, et al. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: a systematic review. PLoS ONE. 2020;15(2):e227475. https://doi.org/10.1371/journal.pone.0227475.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2015;21:3843–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee DY, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5‑fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer. 2007;110:129–37.

    Article  PubMed  Google Scholar 

  24. Lee BH, Lee DS, Cho CW, Yun SS. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. World J Surg Oncol. 2019;17:143.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Hamaoka M, Kobayashi T, Kuroda S, Iwako H, Okimoto S, Kimura T, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retrospective cohort study. Int J Surg. 2017;44:223–8.

    Article  PubMed  Google Scholar 

  26. Kondo M, Morimoto M, Kobayashi S, et al. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP‑2 trial. BMC Cancer. 2019;19(1):954. https://doi.org/10.1186/s12885-019-6198-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lee BH, Lee DS, Cho CW, Yun SS. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. World J Surg Oncol. 2019;17(1):143. https://doi.org/10.1186/s12957-019-1685-6.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Lyu N, Zhao M. Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase 3 trial (The FOHAIC‑1 study). J Clin Oncol. 2021;39(15_suppl):4007–4007.

    Article  Google Scholar 

  29. Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61(6):1968–77. https://doi.org/10.1002/hep.27752.

    Article  PubMed  Google Scholar 

  30. Ravaioli M, Odaldi F, Cucchetti A, et al. Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. Sci Rep. 2019;9:3781. https://doi.org/10.1038/s41598-019-40543-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kudo M. Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update. Liver Cancer. 2020;9:640–62. https://doi.org/10.1159/000511001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T‑Y, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3_suppl):267–267.

    Article  Google Scholar 

  33. Kaseb A, Vence L, Blando J, Yadav S. Open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC. Ann Oncol. 2019;37:abstr 4098.

    Google Scholar 

  34. Kaseb A, Vence L, Blando J, Yadav S, Ikoma N, Pestana RC, et al. Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma. Cancer Immunol Res. 2019;7:1390–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Yarchoan M, Zhu Q, Durham JN, Gross N, Charmsaz S, Leatherman JM, et al. Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3_suppl):335–335.

    Article  Google Scholar 

  36. Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: A randomized, open-label, multicenter controlled study. J Clin Oncol. 2019;37(24):2141–51. https://doi.org/10.1200/JCO.18.02184.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General and Visceral Surgery, Salzkammergut Klinikum Vöcklabruck, Vöcklabruck , Austria, Dr. Wilhelm-Bock-Str. 1, 4840

    Iveta Urban

Authors
  1. Iveta Urban
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Florian Primavesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Klaus Bogner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claudia Bartsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marlene Trattner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexandra Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stefan Stättner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Iveta Urban.

Ethics declarations

Conflict of interest

I. Urban, F. Primavesi, K. Bogner, C. Bartsch, M. Trattner, A. Schmid and S. Stättner declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Urban, I., Primavesi, F., Bogner, K. et al. Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome. memo 15, 5–11 (2022). https://doi.org/10.1007/s12254-021-00791-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-021-00791-5

Keywords

Search

Navigation